FLSM
DCPH

Frazier Life Sciences Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Frazier Life Sciences Management’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,455,837
Closed -$22.9M – 56
2024
Q1 		$22.9M Buy
1,455,837
+434,037
+42% +$6.68M 0.97% 29
2023
Q4 		$16.5M Buy
1,021,800
+651,800
+176% +$8.31M 0.88% 31
2023
Q3 		$4.71M Hold
370,000
– – 0.31% 45
2023
Q2 		$5.21M Buy
+370,000
New +$5.29M 0.31% 41

Other funds holding DCPH

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Frazier Life Sciences Management's DCPH Position: Q2 2024 in Review

Frazier Life Sciences Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 1,455,837 shares — an estimated $22.9M sold.

Frazier Life Sciences Management first reported a position in DCPH in Q2 2023 and held it in 4 quarters. The position peaked at $22.9M in Q1 2024. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

  • Frazier Life Sciences Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Frazier Life Sciences Management sold 1,455,837 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $22.9M.
  • Frazier Life Sciences Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 4 quarters.
  • Frazier Life Sciences Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $22.9M in Q1 2024.
  • 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Frazier Life Sciences Management's 13F filing for Q2 2024, filed 15 Aug 2024.